KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Twist Bioscience (TWST) EPS (Weighted Average and Diluted) (2020 - 2025)

Twist Bioscience (TWST) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with -$0.81 as the latest value for Q3 2023.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 8.99% to -$0.81 in Q3 2023 year-over-year; TTM through Sep 2023 was -$3.6, a 10.67% increase, with the full-year FY2025 number at -$1.3, up 63.89% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.81 for Q3 2023 at Twist Bioscience, up from -$1.01 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.62 in Q3 2020 to a low of -$1.15 in Q1 2022.
  • A 4-year average of -$0.89 and a median of -$0.86 in 2021 define the central range for EPS (Weighted Average and Diluted).
  • Biggest YoY gain for EPS (Weighted Average and Diluted) was 18.68% in 2022; the steepest drop was 47.44% in 2022.
  • Twist Bioscience's EPS (Weighted Average and Diluted) stood at -$0.62 in 2020, then plummeted by 46.66% to -$0.91 in 2021, then grew by 18.68% to -$0.74 in 2022, then decreased by 9.46% to -$0.81 in 2023.
  • Per Business Quant, the three most recent readings for TWST's EPS (Weighted Average and Diluted) are -$0.81 (Q3 2023), -$1.01 (Q2 2023), and -$1.04 (Q1 2023).